CDKN2A and peritoneal mesothelioma: Third, given the similar genomic landscape of both pleural and peritoneal mesothelioma (copy number-driven somatic alterations including high BAP1 and CDKN2A inactivation frequency), there was no expectation of widely differing responses to anti-PD-1 checkpoint inhibition between these subtypes.